DHTKD1 and ovarian carcinoma: Although a clinical trial of E1A gene therapy using tgDCC-E1A (E1A-lipid complex) combined with paclitaxel treatment for patients with platinum-resistant ovarian cancer was terminated at phase I/II of the study due to low accrual (ClinicalTrials.gov Identifier: NCT00102622), the results will be valuable for developing an efficient combination of E1A gene therapy with other agents in the future.